biosimilars market
[Industry Update] The changing biosimilars landscape in Latin America
June 04 by Pharma IQTTY Biopharma and the Mexican Pharmaceutical Institute share their insight on regulatory and market changes in Latin America around biosimilars
Market Snapshot - Top 10 Biosimilars Manufacturers 2015
May 28 by Pharmaceuticals & Biotechnology EditorWith the approval of the first biosimilar product in the United States this year, cost containment pressures and a pending patent cliff, Pharma IQ takes a closer look at the current biosimilars mark...
Pharma & Outsourcing Practice: Biosimilars - Guidelines, Players, Providers
June 01 by Pharmaceuticals & Biotechnology EditorIN THIS ISSUE: Outsourcing for biosimilars Approvals and guidance Biosimilar monoclonal antibodies Players and their responsibility Service Providers GET THE COMPLETE REPORT...
Biosimilars: Prioritising the Emerging Market Opportunity
September 01 by Pharmaceuticals & Biotechnology EditorBy 2015, approximately USD73 billion of biologic sales are projected to lose patent protection, opening the door for the entry of biosimilar versions of these agents. The majority of agents losing p...
Biosimilar Capabilities and Market Potential in Asia
June 29 by Pharma IQEpogen, Neupogen and Enbrel are three biologics which have already seen their patents expire, and Herceptin and Avastin are to be added to this list in the not too distant future. By 2015 the global...
FDA to Issue Guidance on the Biosimilar Pathway by End of 2011
May 17 by Pharma IQIt was only matter of time before the United States Food and Drug Administration (FDA) put in place guidance for the marketing of biosimiliars – and it would seem that time is almost upon us. Global...